Compare Celsius Holdings, Inc. (CELH) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs Ginkgo Bioworks Holdings Inc — how do they compare? Celsius Holdings, Inc. trades at $30.16 (market cap $7.71B), while Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M). The key difference: Celsius Holdings, Inc. is far larger — about 13.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CELH | DNA | |
|---|---|---|
Market Cap | $7.71B | $590.53M |
Sector | Consumer Staples | Health |
52-Week High | $64.86 | $16.14 |
52-Week Low | $27.75 | $5.48 |
Enterprise Value | $9.58B | $627.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Celsius Holdings (CELH) trades at $29.83, down 2.52% on the day, amid bearish technical signals despite strong analyst support. The stock shows robust revenue growth, with 2025 sales reaching $2.52B, though net margins have compressed to 4.29%. Recent quarters consistently beat EPS estimates, but cash flow turned negative due to heavy investing activity. Legal investigations and competitive pressures weigh on sentiment, while a $52.30 consensus price target implies significant upside.
Outlook remains bifurcated: high growth potential and international expansion contrast with margin pressure and litigation risks. Investors face a volatile growth story where execution on profitability and market share gains will dictate performance. The stock's high P/E of 71.16 demands sustained earnings acceleration to justify valuation.
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
